Objective: Temporal lobe epilepsy (TLE) is a chronic epilepsy syndrome defined by seizures and progressive neurological disabilities, including cognitive impairments, anxiety, and depression. Here, human TLE specimens were investigated focusing on the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) and complex 2 (mTORC2) activities in the brain, given that both pathways may represent unique targets for treatment. Methods: Surgically resected hippocampal and temporal lobe samples from therapy-resistant TLE patients were analyzed by western blotting to quantify the expression of established mTORC1 and mTORC2 activity markers and upstream or downstream signaling pathways involving the two complexes. Histological and immunohistochemical techniques were used to assess hippocampal and neocortical structural abnormalities and cell-specific expression of individual biomarkers. Samples from patients with focal cortical dysplasia (FCD) type II served as positive controls. Results: We found significantly increased expression of phospho-mTOR (Ser2448), phospho-S6 (Ser235/236), phospho-S6 (Ser240/244), and phospho-Akt (Ser473) in TLE samples compared to controls, consistent with activation of both mTORC1 and mTORC2. Our work identified the phosphoinositide 3-kinase and Ras/extracellular signalregulated kinase signaling pathways as potential mTORC1 and mTORC2 upstream activators. In addition, we found that overactive mTORC2 signaling was accompanied by induction of two protein kinase B-dependent prosurvival pathways, as evidenced by increased inhibitory phosphorylation of forkhead box class O3a (Ser253) and glycogen synthase kinase 3 beta (Ser9).
underlying epileptogenesis, including the associated cognitive and neuropsychiatric comorbidities, in TLE patients may provide novel opportunities for pharmacological intervention.
The mechanistic target of rapamycin (mTOR) plays critical roles in normal brain function and has recently emerged as a possible key signaling pathway implicated in epileptogenesis, including seizure-induced comorbidities, [3] [4] [5] [6] [7] [8] [9] [10] and therefore a target for such treatments.
Hyperactivation of mTOR signaling has been associated with several human neurodevelopmental epilepsy disorders, such as tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD), 11 but also observed in other epilepsy pathologies, including TLE and Rasmussen's encephalitis. [12] [13] [14] mTOR forms two structurally and functionally distinct complexes (Fig 1) , called mTORC1 and mTORC2. 15, 16 mTORC1 signaling is inhibited by rapamycin and its derivatives, whereas mTORC2 is insensitive to such treatments. Rapamycin-sensitive mTORC1 promotes protein synthesis, cell growth, and proliferation through activation of ribosomal protein S6 kinases (S6K1/2) and inhibition of the eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1). mTORC1 also induces lipid and nucleotide synthesis and suppresses autophagy, a process by which unnecessary or dysfunctional cellular components are degraded. 15, 16 Rapamycininsensitive mTORC2 promotes cell survival through activation of Akt/protein kinase B (PKB), 17 which, in turn, phosphorylates and inactivates several proapoptotic factors such as the transcription factor, forkhead box class O3a (FoxO3a), and glycogen synthase kinase 3 beta (GSK-3b). 18, 19 In addition, mTORC2 is a key regulator of the actin cytoskeleton. 16 Activities of mTORC1 are mainly regulated by the phosphatidylinositol-3-kinase (PI3K)/Akt and Ras/extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathways, which can be induced by insulin, growth factors, neurotransmitters, or cytokines.
15 mTORC2 is also activated by PI3K through a currently unknown mechanism (Fig 1) . Induction of mTORC1 and mTORC2 signaling in neurons is activity dependent. 20 Importantly, seizures and status epilepticus (SE) increase mTORC1, [3] [4] [5] [7] [8] [9] [10] [21] [22] [23] [24] while transiently inhibiting mTORC2 signaling. 25 Despite compelling experimental evidence supporting a role for mTORC1 in promoting epileptogenesis, its activation status in human drug-resistant TLE has been FIGURE 1: Main upstream regulators and downstream effectors of mTORC1 and mTORC2 signaling pathways relevant to epilepsy. Neurotransmitters, growth factors, cytokines, and hormones (insulin) activate their membrane-bound receptors to recruit the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) and Ras/extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathways and activate mTORC1 and mTORC2. The PI3K pathway activates mTORC1 through phosphoinositidedependent kinase 1 (PDK1)-mediated phosphorylation of Akt on its activation loop (Thr308). PI3K also activates mTORC2 through an unknown mechanism. Ras activates mTORC1 by a parallel pathway through activation of MEK1/2 (ERK kinases) and phosphorylation of ERK. The mTOR protein is part of both complexes and can undergo phosphorylation at multiple sites, including Ser2448. mTORC1 controls protein synthesis through activation of ribosomal S6 kinases 1/2 (S6K1/2) and inhibition of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). S6K1/2 activate the ribosomal protein S6 through phosphorylation at Ser235/236 and Ser240/244. Of note, Ser 235/236 may also be phosphorylated by the p90 ribosomal S6 kinase (RSK), further downstream from ERK. mTORC2 controls several neuroprotective signaling pathways through phosphorylation of Akt at Ser473, which, together with the PDK1-mediated phosphorylation at Thr308, results in full Akt activation. Once activated, Akt translocates to various subcellular compartments, including the nucleus, where it phosphorylates the proapoptotic transcription factor forkhead box class O3a (FoxO3a). Phosphorylation at Ser253 by Akt leads to rapid translocation of FoxO3a from the nucleus to the cytoplasm, preventing its binding to the promoter of apoptotic genes, with a net prosurvival effect. In the cytoplasm, Akt can phosphorylate glycogen synthase kinase 3beta (GSK-3b) at Ser9, inhibiting its kinase activity, and preventing the phosphorylation of further downstream targets, including the microtubule-binding protein tau and the transcription factor, nuclear factor E2-related factor 2 (Nrf2). mTORC 5 mechanistic target of rapamycin complex.
only demonstrated by immunohistochemical analysis. [12] [13] [14] Furthermore, no studies to date have evaluated the activation status of mTORC2 signaling in the human TLE brain, although several preclinical studies suggest that diminished mTORC2-dependent negative regulation of proapoptotic pathways may be responsible for acute seizure-induced neuronal death. [25] [26] [27] Therefore, here we examined the activation status of both mTORC1 and mTORC2 in hippocampus and temporal lobe cortex from therapy-resistant TLE patients and control cases by combining quantitative western blot analysis and immunohistochemistry. We also characterized potentially targetable upstream mechanisms leading to mTOR dysfunction and defined downstream prosurvival signaling events linked to altered mTORC2 function. Given the central role of mTOR in oncogenesis, a growing number of promising agents targeting these pathways are entering phase I to III clinical trials for various cancers.
Given that these agents may represent new therapeutic tools for epileptic brain disorders, there is a great need for better understanding of the mechanisms governing mTOR signal transduction in the context of chronic epilepsy.
Materials and Methods

Human Subjects
The TLE study population (Supplementary Table 1 ) consisted of 14 patients who had undergone surgery for resection of epileptogenic region at the University of Pennsylvania (Philadelphia, PA) from March 2013 to March 2016 (10 females and 4 males). Cortical specimens from 2 male patients with chronic epilepsy attributed to hemimegalencephaly and FCD were also included and served as positive controls. All patients were prospectively enrolled in the study, and informed consent for use of brain tissue and for access of medical records was obtained from all individuals before surgery. The study was reviewed and approved by the local institutional review board. Presurgical data and postoperative outcomes were reviewed by a boardcertified neurologist (K.A.D.). All surgeries were performed by the same neurosurgeon (T.H.L.) and consisted of temporal lobectomy, including en-bloc excision of the hippocampal formation, amygdala, and parahippocampal gyrus. All surgical specimens were reviewed independently from the primary clinical review process by the same neuropathologist (M.M.L.), and the criteria for hippocampal sclerosis (HS) were based on the current International League Against Epilepsy (ILAE) classification. 28 Cortical dysplasia type was assigned based on the ILAE consensus classification. 29 The control group consisted of 6 autopsy cases without known neurological or psychiatric history, including epilepsy (3 females and 3 males). Specimens were obtained from the Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD) and were age and region matched to the epilepsy samples. The autopsy was performed within 6 to 18 hours of death (mean, 11.8). We specifically limited our study to cases with a postmortem interval (PMI) less than 24 hours, because we have previously reported no effect of PMI on mTORC1 and mTORC2 activation markers within this time interval. 30, 31 All control cases were assessed by the same neuropathologist and were diagnosed as histologically normal (Fig 3A,B) .
Tissue Preparation
At the time of surgery, hippocampal and temporal lobe specimens were divided into representative tissue blocks, fixed in 10% formalin, embedded in paraffin, and used for standard histopathological diagnostic evaluation. Subsequently, blocks with representative pathology and good tissue preservation were selected for additional immunohistochemistry. Adjacent samples were either fixed in 4% paraformaldehyde (PFA) for immunofluorescence double labeling or immediately frozen for western blot analysis. Autopsy tissue blocks were received either fixed in 10% formalin or frozen.
Immunohistochemistry
Paraffin-embedded TLE and control samples were sectioned at 6 lm. Immunohistochemistry was performed using antibodies against human nonphosphorylated neurofilament RMD020, phosphorylated neurofilament TA51, glial fibrillary acidic protein (GFAP), CD68, CD163, phospho-S6 (Ser235/236), phospho-S6 (Ser240/244), and phospho-Akt (Ser473; all listed in Supplementary . Actin, glyceraldehyde 3-phosphate dehydrogenase, and lamin A/C were used to control for differences in protein loading, and normalized values are expressed as percentage of the mean control samples run on the same blot. Phosphorylated proteins to total protein ratios were calculated in a similar manner.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (v.6.0b; GraphPad Software Inc., San Diego, CA). Group means were compared by unpaired t tests, whereas Pearson correlation analysis was used to establish potential associations between variables. Differences were considered statistically significant at p 0.05.
Results
Clinical and Neuropathological Characterization of Study Population
Mean age at surgery in the TLE group (Supplementary Table 1 ) was 35.6 years (range, 20-56), with an average age at seizure onset of 19.1 years (range, 1-36) and a mean duration of epilepsy of 16.5 years (range, 2-42). Predominant seizure types were medically intractable focal onset, impaired awareness seizures (n 5 13), followed by focal onset, aware (n 5 10) and focal to bilateral tonic clonic seizures (n 5 10). All but 1 patient experienced more than one seizure type at surgery. All TLE patients were on polytherapy with two or more antiepileptic drugs. All but 2 patients had undergone intracranial electroencephalography monitoring, including depth electrode placement for seizure onset localization, which revealed either an amygdalohippocampal (n 5 7) or a neocortical focus (n 5 5). The majority of TLE patients (10 of 14) presented epilepsy risk factors, including head trauma (n 5 5), a family history of epilepsy or febrile seizures (n 5 5), dual pathology (primary lesion within the ipsilateral temporal lobe or hemisphere 28 (n 5 2), status postcraniopharyngioma resection (n 5 1), febrile seizures (n 5 1), and comorbid autism (n 5 1). Hippocampal histopathology assessment revealed hippocampal sclerosis (HS) in 9 of 14 patients, whereas the remaining 5 presented only with gliosis or mild neuronal loss and were classified as no-HS. 28 Examination of the temporal lobe cortex revealed mild to moderate subpial and cortical gliosis. Seizure outcome was assessed conform to Engel's classification. 32 Mean age at surgery for the FCD cohort was 46.5 years (45 and 48 years), with an average duration of epilepsy of 39.5 years (45 and 34 years). Both specimens originated from temporal lobe neocortex, and both surgeries led to Engel class I outcomes (Supplementary Table 1 ). Histopathological features were consistent with FCD type IIa and FCD type IIb, respectively. Mean age of the control group was 38.5 years (range, 19-58), which did not differ significantly from the TLE group (p 5 0.58). All control subjects died of non-neurological causes: arteriosclerotic cardiovascular disease (n 5 3), asthma (n 5 1), acute pancreatitis (n 5 1), and asphyxia by hanging (n 5 1).
Increased mTORC1 and mTORC2 Activation in Human TLE First, we used western blot analysis to assess the phosphorylation of mTOR itself using antibodies against phospho-mTOR (Ser2448). We found that the ratios of p-mTOR (Ser2448)/mTOR were significantly increased in TLE patients compared to nonepilepsy controls, both in the hippocampus (Fig 2A,B ) and temporal lobe cortex (Fig 2F,G) . To determine the activation state of individual complexes, we next used antibodies against established mTORC1-and mTORC2-specific substrates. 15 Levels of mTORC1 activation were measured by assessing the phosphorylation of ribosomal protein S6 using antibodies against phospho-S6 (Ser235/236) and phospho-S6 (Ser240/244). Both p-S6 (Ser235/236)/S6 and p-S6 (Ser240/244)/S6 ratios were significantly increased in TLE hippocampus (Fig 2A,C ,D) and temporal lobe cortex ( Fig 2F,H,I ), compared to controls. To determine mTORC2 activity, we measured p-Akt (Ser473) levels and similarly found significantly increased p-Akt (Ser473)/Akt ratios in TLE relative to controls, both in the hippocampus (Fig 2A,E) and cortex samples (Fig 2F,J) . As expected, cortical tissue from FCD type II cases showed increased mTOR (Ser2448) phosphorylation and enhanced activation of downstream proteins related to both mTORC1 and mTORC2 pathways ( Fig.  2F -J).
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Next, we performed correlation analyses in TLE patients to establish potential associations of these markers with clinical variables (Table) . Hippocampal tissue analysis demonstrated no association between epilepsy duration and expression levels of p-mTOR (Ser2448), or specific mTORC1 and mTORC2 activation markers. In addition, no statistically significant differences were observed with respect to the underlying hippocampal pathology. However, we found that both p-S6 (Ser240/244)/S6 and p-Akt (Ser 473)/Akt levels were significantly higher when the seizure focus was located within the mesial temporal lobe structures, as opposed to the neocortex. Although we found robust mTORC1 and mTORC2 induction in temporal lobe cortex, no relationships with clinical variables were observed within this brain region.
Immunostaining of hippocampal tissue with p-S6 (Ser235/236) and p-S6 (Ser240/244) showed weak immunoreactivities throughout all hippocampal subfields in the control group ( Figure 3C,D) , in contrast to strong labeling of pyramidal neurons in the subiculum and CA1 to CA4 regions in TLE cases (Fig 3E,F) . The granule cell layer (GCL) demonstrated less reactivity for both p-S6 antibodies, consistent with previous reports. 12, 14 Nonneuronal labeling was quite evident in all TLE cases ( Fig  3G-O) , in particular for the p-S6 (Ser235/236) FIGURE 2: Expression of mTORC1 and mTORC2 activation markers is increased in hippocampus and temporal lobe cortex from patients with therapy-resistant TLE compared to controls. (A-E) Hippocampal tissue analysis showing (A) representative western blot images for individual proteins and calculated ratios, expressed as % of control mean, for (B) phospho-mTOR (Ser2448)/mTOR (1,640 6 156% in TLE, n 5 8 vs 100 6 13% in controls, n 5 5), (C) phosho-S6 (Ser235/236)/S6 (823 6 52% in TLE, n 5 11 vs 100 6 13% in controls, n 5 5), (D) phospho-S6 (Ser240/244)/S6 (1,381 6 294% in TLE, n 5 11 vs 100 6 20% in controls, n 5 5), and (E) phospho-Akt (Ser473)/Akt (1,981 6 362% in TLE, n 5 11 vs 100 6 43% in controls, n 5 5). (F-J) Temporal lobe cortex analysis showing (F) the representative western blot bands and quantitative analysis for (G) phospho-mTOR (Ser2448)/mTOR (447 6 36% in TLE, n 5 12 vs 100 6 24% in controls, n 5 5 and 411 6 97% in FCD, n 5 2), (H) phosho-S6 (Ser235/236)/S6 (1383 6 301% in TLE, n 5 10 vs. 100 6 13% in controls, n 5 6 and 508 6 283% in FCD, n 5 2), (I) phospho-S6 (Ser240/244)/S6 (2098 6 399% in TLE, n 5 13 vs. 100 6 12% in controls, n 5 6 and 1234 6 154% in FCD, n 5 2), and (J). Phospho-Akt (Ser473)/Akt (2,106 6 162% in TLE, n 5 10 vs 100 6 25% in controls, n 5 6 and 955 6 199% in FCD, n 5 2). *, **, ****: Denotes p < 0.05, p < 0.01, and p < 0.0001, respectively (unpaired t tests comparing non-epilepsy control and TLE groups) Error bars indicate SEM. Akt 5 protein kinase B; FCD 5 focal cortical dysplasia; mTORC 5 mechanistic target of rapamycin complex; TLE 5 temporal lobe epilepsy.
antibodies. Many of these cells colabeled with CD68 or GFAP, specific cell markers of activated microglia and astrocytes, respectively (Fig 3K,N, insets) . Immunohistochemistry for mTORC2 activity marker p-Akt (Ser473) demonstrated low expression levels in control hippocampal tissue (Fig 4A-C) . In contrast, we observed increased nuclear and cytoplasmic neuronal labeling in TLE cases, both in nonsclerotic ( Fig  4D-F) and sclerotic (Fig 4G-I) hippocampus samples. Altered p-Akt (Ser473) subcellular localization in TLE hippocampal tissue was confirmed by additional western blotting after separation of protein extracts into cytoplasmic and nuclear fractions (8,595 6 552% of control, p < 0.0001 in the cytoplasm; 325 6 56% of control, p < 0.05 in the nucleus; data not shown). We also observed robust p-Akt (Ser473) immunoreactivity in activated microglia (Fig 4J-L) , and to some extent in reactive astrocytes (Fig 4M-O) . In the temporal lobe cortex, we observed a similar low expression for p-S6 (Ser235/ 236), p-S6 (Ser240/244), and p-Akt (Ser473) in controls, but increased neuronal labeling in TLE cases (data not shown). For all markers, staining was most prominent in layer III and V pyramidal neurons. Similar to the hippocampal formation, we confirmed activated mTORC1 and mTORC2 signaling in cortical microglia and astrocytes by double label immunohistochemistry for p-S6 (Ser235/236) or p-Akt (Ser473) and the corresponding cell markers (data not shown).
The PI3K and Ras/ERK Signaling Pathways Are Induced in Human TLE The PI3K and Ras/ERK pathways represent two major signaling transduction pathways that can activate mTOR. Because both signaling pathways can be activated by seizures, 4, 41 we sought to determine whether these patterns observed in animal models are also present in humans.
Because the protein kinase activities of both mTORC1 and mTORC2 are increased by PI3K activation, we first carried out western blot analysis of TLE and control tissue homogenates to determine expression of phospho-Akt (Thr308), because this site is specifically phosphorylated upon PI3K activation by phosphoinositide-dependent kinase 1. 15 We found a significant increase in phosphoAkt (Thr308)/Akt ratios in the TLE hippocampus ( Fig  5A,B) , but no significant changes in the temporal lobe cortex relative to nonepilepsy controls (Fig 5D,E) . We next assessed expression levels of pospho-ERK1/2 (Thr202/Tyr204), two residues that are specifically 
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targeted by the ERK kinases, MEK1 and MEK2, downstream from Ras. 15 Western blot quantification of phospho-ERK1/2 (Thr202/Tyr204)/ERK ratios showed significant increases in TLE cases, both in the hippocampus (Fig 5A,C) and temporal lobe cortex (Fig 5D,F) . As further shown in Figure 5D -F, FCD type II cortical specimens presented a more variable PI3K and Ras/ERK induction, when compared to TLE cortex. Subsequent correlation analyses in TLE patients demonstrated no association between hippocampal levels of p-Akt (Thr308)/Akt and epilepsy duration or underlying pathology; however, we found that hippocampal pAkt (Thr308)/Akt levels were significantly higher in cases with mesial temporal onset, consistent with the results obtained regarding mTORC1 and mTORC2 activation markers (Table) . In contrast, hippocampal p-ERK1/2 (Thr202/Tyr204)/ERK levels correlated strongly with the duration of epilepsy, but we found no statistically significant differences with respect to seizure focus location, or the presence or absence of HS. Again, cortical tissue analysis revealed no relationships with clinical variables. Double label immunohistochemistry for p-Akt (Thr308) and p-ERK1/2 (Thr202/Tyr204), along with the neuronal marker, neuronal nuclei (NeuN), showed a similar regional and cell-specific expression pattern. In the hippocampus, we found strong labeling of the subiculum and CA1 to CA4 regions, but lower expression in the GCL (Fig 5G-O ; only p-ERK is shown). In the temporal lobe cortex, both antibodies showed robust labeling of layer III and V pyramidal neurons (data not shown). In addition, within both brain regions, there was widespread p-Akt (Thr308) and p-ERK1/2 (Thr202/Tyr204) expression in non-neuronal cells, in a pattern similar to mTORC1 and mTORC2 activity markers.
Decreased FoxO3a Signaling in Human TLE
To further investigate potential downstream effects of overactive mTORC2 signaling in TLE tissue, we next evaluated the phosphorylation status and subcellular localization of FoxO3a, a key proapoptotic transcription factor that is suppressed by nuclear Akt signaling. Akt phosphorylates FoxO3a at several residues, including Ser253, which results in its nuclear export and subsequent suppression of proapoptotic genes transcription. 42 Western blot quantification of TLE, FCD, and control samples demonstrated significantly increased phoshoFoxO3a (Ser253)/FoxO3a ratios in TLE hippocampus and cortex (Fig 6A-D) , but only a modest increase in FoxO3a phosphorylation in FCD type II cases (Fig  6C,D) . Interestingly, we found no correlations between ) representative bands for individual subunits and quantification for (E) phospho-Akt(Thr308)/Akt (114 6 11% in TLE, n 5 10 vs 100 6 8% in controls, n 5 6 and 68 6 43% in FCD, n52), and (F) phospho-ERK(Thr202/Tyr204)/ERK (183 6 15% in TLE, n 5 9 vs 100 6 3.8% in controls, n 5 6 and 463 6 349% in FCD, n 5 2). **, ***, ****: Denotes p < 0.01, p < 0.001, and p < 0.0001, respectively (unpaired t tests comparing nonepilepsy control and TLE groups). p-FoxO3a (Ser253)/FoxO3a and epilepsy duration, seizure focus location, or hippocampal pathology in our TLE cohort (Table) .
Double labeling for NeuN and FoxO3a revealed predominant cytoplasmic expression in both nonsclerotic (Fig 6E-G) and sclerotic (Fig 6H-J) hippocampus samples, consistent with a strong antiapoptotic response in both conditions. Besides neurons, robust cytoplasmic FoxO3a expression was also noted in glial and endothelial cells. A similar expression pattern was observed in the temporal lobe cortex (data not shown).
Suppression of GSK-3b Signaling in Human TLE
GSK-3b represents another important downstream target of Akt. Phosphorylation of constitutively active GSK-3b at Ser9 by Akt results in GSK-3b inactivation. 18 Similar to p-FoxO3a, western blot analysis of TLE hippocampal and cortical samples demonstrated significantly increased phospho-GSK-3b (Ser9)/GSK-3b levels in both brain regions (Fig 7A-D) . A comparable increase in p-GSK-3b (Ser9)/GSK-3b levels was observed in FCD type II cortical tissue. We found no statistically significant correlations with clinical variables in TLE patients; however, hippocampal tissue analysis showed a trend toward decreased p-GSK-3b (Ser9)/GSK-3b expression with longer duration of epilepsy (Table) . Immunohistochemistry for p-GSK-3b (Ser9) and NeuN demonstrated robust neuronal and non-neuronal expression throughout all hippocampal sectors, without any noticeable differences in p-GSK-3b (Ser9) expression pattern between the nonsclerotic ( Figure 7E -G) and sclerotic (Fig 7H-J) hippocampus, but consistent with the western blot data, diminished p-GSK-3b (Ser9) expression with longer epilepsy history. In the temporal lobe cortex, phospho-GSK3b (Ser9) expression was expressed predominantly in layer III and V pyramidal neurons and in the blood vessels endothelium (data not shown).
Discussion
Our study provides the first quantitative analysis of numerous steps in mTOR-related signaling in human therapy-resistant TLE, as opposed to previous work, which was limited to immunohistochemical analyses of mTORC1 downstream signaling, 12-14 without quantitative comparisons of major components of the mTORC1 and mTORC2 pathways. Here, we show that both complexes are highly activated in TLE, and that these changes are not confined to the primary seizure focus, but involve the anterior temporal lobe structures more broadly. Nevertheless, our data show that activation of both mTORC1 and mTORC2 is more prominent in the brain regions where the electrographic seizure activity is greatest. In addition, our results establish, for the first time, that two neuroprotective signaling pathways downstream from mTORC2, the Akt/FoxO3a and the Akt/ GSK-3b pathways, are strongly induced in TLE. Our work also identifies PI3K and Ras/ERK1/2 signaling pathways as upstream activators of mTORC1 and mTORC2 and as potential new targets for treatment.
Importantly, our data demonstrate that many of the same molecular changes reported in preclinical studies during different stages of epileptogenesis are still present in human chronic TLE. Duration of epilepsy varied greatly among our patients (2-42 years), yet we found no correlation between epilepsy duration and mTORC1 or mTORC2 activity levels, suggesting an extended window for antiepileptogenic and neuroprotective therapeutic interventions. We also acknowledge several inherent limitations, common to all epilepsy human tissue studies. First, our study cannot establish whether these differences represent intrinsic brain properties that precede the development of epilepsy, or reflect molecular responses to seizures. In addition, we cannot exclude independent effects of antiepileptic drug treatment, because, as a result of the small number of cases, we were unable to analyze this statistically. mTORC1-dependent protein synthesis and its role in synaptic development and plasticity are well established, suggesting that altered mTORC1 signaling in TLE may have a profound impact on brain function and contribute to some of its cognitive comorbidities. Developing neurons require mTORC1 activity for dendritic and axonal growth 30, [43] [44] [45] and for the establishment of proper excitatory/inhibitory (E/I) balance. 31, [46] [47] [48] Neurons also require mTORC1 activity for long-term synaptic potentiation (LTP) and long-term depression, two activity-driven processes involved in learning and memory. [49] [50] [51] [52] mTORC1 is activated in experimental epilepsy models, most prominently in the hippocampus, but also in other areas of the brain, such as neocortex and amygdala. 4, [8] [9] [10] 12, [21] [22] [23] Activation of mTORC1 occurs within hours post-SE induction and, depending on the model, persists up to several weeks or even months post-SE. 5, [8] [9] [10] 12 The initial increase in mTORC1 activity (the first 24 hours) occurs mostly in neurons and is followed by sustained activation in glial cells. 4, 5, 10, 22 The synaptic reorganization of the hippocampal circuitry, in particular those connections involving the hippocampal dentate GCL, is thought to play a causative role in TLE. 53, 54 Several TLE models have shown upregulated mTORC1 activity in the GCL, 12, 22, 55 suggesting that mTORC1 may promote cellular hypertrophy, induce sprouting of GC axons (mossy fibers), enhance basal dendrites formation, and lead to aberrant hippocampal neurogenesis, which, in turn, may promote epileptogenesis. Indeed, rapamycin can effectively suppress post-SE GCL hypertrophy and mossy fiber sprouting, preventing establishment of recurrent excitation in the dentate gyrus and development of epilepsy. [8] [9] [10] 21, 56, 57 Remarkably,
Talos et al: mTOR Activation in Temporal Lobe Epilepsy delayed rapamycin treatment, initiated after the establishment of epilepsy, is still able to reduce seizure activity and mossy fiber sprouting, 9 but the seizure-suppressing effects are transient. In addition, rapamycin can prevent the sprouting of CA3/mossy cells axons onto the proximal dendrites of granule cells, 58 suggesting much broader drug effects on post-SE hippocampal synaptic reorganization. Noteworthy, rapamycin can also suppress the sprouting of inhibitory hilar neurons axons, which may possibly have negative net effects on hippocampal hyperexcitability. 59 Besides inhibiting mossy fiber sprouting, rapamycin has little or no effect on other SE-induced GCL phenotypes, including basal dendrite formation and ectopic granule cell generation, 57, 60, 61 which may explain the negative results on seizure prevention in some models. 57, 60 Another potential mechanism by which increased activation of mTORC1 within the temporal lobe structures may promote epileptogenesis is by altering expression and function of neurotransmitter receptors and ion channels, given that previous studies have demonstrated that rapamycin treatment prevented seizure-induced enhancement of glutamatergic function 4 and reversed several ion channels abnormalities in hippocampal neurons. 5 Besides altered protein synthesis, defects in autophagic clearance of cellular proteins and organelles attributed to mTORC1 activation may also be involved in epileptogenesis, although the exact downstream mechanisms remain to be elucidated. Impaired autophagy may contribute to neurodegeneration and cell death, 62 or may increase neurotransmitter release, given that local presynaptic autophagy plays an important role in degradation of synaptic vesicles. 63 The observation that reactive astrocytes and activated microglia have sustained p-S6 expression within the temporal lobe structures (in particular within the sclerotic hippocampus) 13 suggests a possible role for glial mTORC1 signaling in promoting epileptogenesis.
Indeed, rapamycin was able to reduce SE-induced hippocampal astrogliosis and microgliosis, 5 whereas deletion of mTOR in reactive astrocytes in mice with chronic epilepsy effectively suppressed seizures, without affecting mossy fiber sprouting. 64 Dysfunction of mTORC1 signaling has also been implicated in the pathophysiology of several cognitive disorders, 62, 65, 66 and there is evidence to suggest that it may also contribute to epilepsy comorbidities. Indeed, chronic rapamycin treatment markedly diminished aggressive behavior and cognitive impairments in several TLE models. 5, 6 Similarly, in models of early-life seizures, short-term mTORC1 inhibition was not only antiepileptogenic, but also highly effective in preventing the associated cognitive decline and autistic-like behavior. 4, 7 Although there are abundant data implicating mTORC1 in epilepsy and its comorbidities, along with extensive preclinical experience with mTORC1 inhibitors, information regarding mTORC2 and its relevance to epileptogenesis is still relatively sparse. The mTORC2 pathway seems to be particularly important for neuronal survival under a wide variety of circumstances, an effect mainly mediated by inhibitory phosphorylation of FoxO3a. 25, 67, 68 Indeed, cells with disruption of mTORC2 signaling are more sensitive to apoptosis, 67 whereas constitutive mTORC2 activation in the majority of cancers confers therapy resistance. 69 Besides promoting FoxO3a-dependent antiapoptotic responses, mTORC2 signaling may likely induce a number of neuroprotective mechanisms through the negative regulation of GSK-3b. GSK-3b phosphorylates tau protein making it insoluble, which can lead to neuronal death and degeneration. 70 Whereas hyperphosphorylation of tau is mainly known as an Alzheimer's disease-associated phenotype, recent studies have revealed pathologic tau phosphorylation in several other neurological diseases, including epilepsy. [71] [72] [73] In addition, GSK-3b can inhibit the antioxidant cell responses by directly phosphorylating the transcription factor nuclear factor E2-related factor 2 (Nrf2), a master regulator of redox homoeostasis, 74 and promote proinflammatory and proapoptotic responses in the brain. 75, 76 Our novel finding that mTORC2 signaling is upregulated in TLE is of particular interest, given that seizure-induced oxidative stress, neuroinflammation, neuronal death, and degeneration have been postulated as important mechanisms underlying the epileptogenic process. 77, 78 Our data show that, in human TLE tissue, activated Akt translocates to the nucleus, where it phosphorylates FoxO3a leading to its nuclear export. Interestingly, neither the degree of mTORC2 activity nor of FoxO3a inhibition correlated with epilepsy duration or severity of hippocampal pathology, suggesting that FoxO3a-independent mechanisms may have contributed to cell death in our cases. 79, 80 In addition, we found that GSK-3b is highly inhibited in neurons and glia by the mTORC2-Akt regulatory pathway, and therefore neurons may be protected from tau-induced neurodegeneration, oxidative stress, and excessive production of proinflammatory mediators. However, we observed a trend toward decreased GSK-3b phosphorylation with longer epilepsy duration, which suggests that, over time, GSK-3b inhibition may become insufficient. Therefore, therapies directed toward further activation of mTORC2 in TLE may be critical for improved neuronal survival and therefore may represent a novel strategy for disease modification.
To date, there are several studies reporting altered mTORC2 activity in response to seizures and SE. However, it appears that mTORC2 activity levels are highly dependent on the severity and type of insult, in contrast to mTORC1, which is activated post-SE across models. For example, brief seizure episodes that are not associated with significant neuronal injury, such as those induced by pentylenetetrazole, result in mTORC2 activation, as evidenced by rapid increases in Akt Ser473 phosphorylation. 41 In contrast, in the kainic acid or pilocarpine models, two paradigms that result in acute and chronic injury to the hippocampus, there is an initial robust suppression of mTORC2 activity, persisting up to 1 to 3 days postinjury, which correlates temporally with elevated Bim expression, a readout of FoxO3a transcriptional activity, increased apoptotic cell death, and GSK-3b-dependent tau hyperphosphorylation. [25] [26] [27] 81, 82 At the same time, brain regions that typically do not undergo cell death and degeneration in these models (such as hippocampal CA1 and neocortex) display a strong induction of mTORC2. 27 In contrast, during the latent period and the chronic epilepsy stages, there is increased mTORC2 activity, 5, 83, 84 suggesting that endogenous mechanisms directed to prevent seizure-induced neuronal loss and limit disease progression might be activated at later stages. The mechanism of this "acquired" mTORC2-mediated neuroprotection in chronic epilepsy is not known, but there is evidence that prolonged synaptic activity, in particular activation of synaptic NMDA receptors can induce such changes, 85, 86 raising the intriguing possibility that milder seizures may render temporal lobe structures less susceptible to further neuronal loss. In addition to conferring neuroprotection, mTORC2 regulates several proteins involved in actin cytoskeleton rearrangement, including the protein kinase C-a (PKC-a) and Ras-related C3 botulinum toxin substrate 1 (Rac1). 87, 88 Importantly, by modulating actin dynamics, mTORC2 promotes LTP and memory formation, which further underscores the importance of preserving or activating mTORC2 to enhance memory, or reverse memory loss in TLE. 87, 89 Another important finding of our study is the robust activation of ERK signaling in both hippocampus and temporal cortex of patients suffering from therapyresistant TLE, consistent with previous studies showing upregulated ERK signaling in several neocortical epilepsy syndromes, including TSC and FCD. [90] [91] [92] ERK is upstream of mTORC1 and both kinases are simultaneously induced at activated synapses to regulate local protein synthesis. 20 In addition to activating mTOR, ERK also regulates the activity of cAMP response element binding protein and therefore may be critically involved in seizure-induced dysregulated gene expression. 91 In animal models, ERK signaling is activated in a time-dependent manner following seizures, 4, 84, 93 and augmented ERK signaling has been directly linked with increased seizure susceptibility. 94 Our finding that levels of activated ERK positively correlate with epilepsy duration suggests that adjuvant therapies directed toward ERK inhibition may be of great clinical benefit, especially at later stages. In this study, FCD samples were used as a positive control group, and indeed our study confirms previous reports showing strong induction of both mTORC1 and mTORC2 in these cases. [33] [34] [35] [36] [37] [38] [39] [40] 90 However, our FCD cohort data also revealed several distinct features with respect to upstream and downstream mechanisms. Upstream PI3K signaling did not appear to be activated, but rather suppressed in our FCD cohort, as suggested by lower p-Akt (Thr 308) expression, which apparently contradicts previous studies. 33, [37] [38] [39] [40] However, the small number of samples analyzed here may be responsible for these differences. We also found that mTORC2 induction in FCD was accompanied by strong GSK-3b inhibition, but it seemed insufficient to cause a robust suppression of FoxO3a signaling. A possible explanation for this discrepancy is that in FCD type II specimens, pAkt (Ser473) is mainly expressed in the neuronal cytoplasm and not in the nucleus. 33, 35, 38, 39 
Conclusion
Epileptogenesis involves activation of numerous signaling pathways that ultimately result in synaptic reorganization. The mTORC1 and mTORC2 pathways are clearly engaged in human TLE epileptogenesis. The strong neuroprotective mechanisms triggered by mTORC2 activation is an argument against using a total mTOR blockade by second-generation inhibitors targeting the mTOR catalytic site (dual mTORC1 and mTORC2 inhibitors). Our results are suggesting high responsiveness to mTORC1 inhibitors (rapamycin and rapalogs), which are already used for cancer therapy and are currently under investigation in TSC patients for seizure suppression. However, the chronic use of high-dose rapalogs, in addition to blocking mTORC1 signaling, may also compromise mTORC2 function. Therefore, alternative approaches to selectively modulate mTORC1 and mTORC2 downstream activities, such as the use of p70S6K inhibitors, autophagy inducers, or GSK-3b inhibitors, alone or in combination, seem to be preferable treatment options for epilepsy. Finally, negative regulation of selective pathways upstream of mTORC1 and mTORC2, such as accomplished by ERK inhibitors, may also represent promising approaches for treatment of refractory epilepsy in some patients.
